Press Release Biocartis NV: Five Idylla™ Performance Studies to be Presented at ‘European Society for Medical Oncology’ congress

NEXT STORY
In-vitro Diagnostics Market To Exhibit a CAGR of 4.5%; Adoption Of New Techniques For Rapid Disease Diagnosis Will Encourage Growth, says Fortune Business Insights
PREV STORY
BeiGene Announces Clinical Results on Tislelizumab Presented at the 22nd Annual Meeting of the Chinese Society of Clinical Oncology (CSCO)
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

FIT Biotech Oy: Research grant application related to Innovative Medicines Initiative 2 (IMI2) did not result in a positive decision

FIT Biotech Oy Company Release June 10, 2016 at 19.15 EET          Research grant application ...

author_avatar
NASDAQ Market News

Cesca’s Device Subsidiary, ThermoGenesis, Expands into CAR-T Related Contract Development and Manufacturing (CDMO) Services

RANCHO CORDOVA, Calif., March 14, 2018 (GLOBE NEWSWIRE) -- Cesca Therapeutics Inc. (“Cesca”) (NASDAQ:KOOL), ...

author_avatar
NASDAQ Market News

Roche and Spark Therapeutics, Inc. announce closing of investigation and unconditional clearance by the FTC and expiration of Hart-Scott-Rodino waiting period for acquisition of Spark Therapeutics, Inc

author_avatar
NASDAQ Market News